Dublin, Aug. 16, 2017 -- The "R&D Drug Pipeline Database" newsletter has been added to Research and Markets' offering.
R&D Drug Pipeline Database: 1-Year Subscription
Subscription to this proprietary R&D Drug Pipeline Database provides 24/7 online access to information about more than 21,000 project entries (files) for therapeutic drugs on the market and on investigational drug candidates in research & development.
Pre-established and free search functions allow to identify molecules according to their:
- Product category (NCE, antibodies, proteins, DNA, RNA, cells, vaccines, peptides)
- Technology (e.g. antibody-drug conjugate, bispecific antibody)
- Target (e.g. Her2, Amyloid beta, TNF, PD-1/PD-L1)
- Pipelines (selected by target, therapeutic area, company, technology)
- Sales (for marketed antibodies, peptides and proteins)
- R&D Phase (clinical phases, market, preclinical)
- Territory (countrywise)
- Therapeutic Area (e.g. infectious, oncology, gastrointestinal)
- Drug Code/Name (for individual molecules)
Each project is specified for its Target, Therapeutic Area and R&D Phase. Use of the R&D Drug Pipeline Database is intuitive. Data sets of interest can be printed and exported as reports in Excel or Word format. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. Sales figures of major therapeutic antibodies, proteins and peptides on the market are provided.
An advanced search function allows to combine search parameters. A scroll down menu for predefined targets and technologies conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase or company name.
Special Focus of the Database:
- Antibodies
- Proteins
- Peptides
- Vaccines
Purchase of the subscription provides a 1-year online access to the data of the R&D Drug Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.
Benefits from the R&D Drug Pipeline Database:
- Intuitive use
- 24/7 online access
- Designed for structured searches
- Focused on targets, product categories and R&D phases
- Ideal for competitor analysis (companies, targets, product categories)
- Cost-effective and rapid solution for benchmarking
- Identification of licensing candidates
Project listing in a tabular format:
- Drug Codes
- Target/Mechanism of Action
- Class of Compound
- Product Category
- Company
- Territory
- Therapeutic Area
- Indication
- R&D Phase
Product Categories:
- Antibody
- Cell
- DNA
- Peptide
- Protein
- RNA
- Small Molecule
- Vaccine
Therapeutic Areas:
- Cardiovascular, blood & acute care
- Dermatology
- Gastrointestinal
- Genitourinary, gynecology & renal
- Infectious & toxicology
- Metabolism & endocrine
- Neurology & psychiatry
- Oncology
- Ophthalmolgoy & otorhinolaryngology
- Orthopedics, dental, anesthesia & surgery
- Pulmonary & respiratory
- Rheumatoid & autoimmune
Examples of Predefined Targets of the Scroll Down Menu:
- Antibody-Drug Conjugates (ADC)
- Sales of Antibodies & Proteins 2015
- CAR & TCR Engineered T-Cells and NK Cells
- Adalimumab (Humira) Biosimilars
- Her2 Antibodies
- Amyloid beta-Targeted Antibodies
- CD10-Targeted Immunotherapeutics
- Immunocytokines
- Bispecific Antibodies
- Peptide Sales 2015
- PD-1 & PD-L1 Immune Checkpoint Inhibitors
- Zika Virus Vaccines
- Coagulation Factors
- Botulinum Neurotoxins
- Human Papilloma Virus (HPV) Vaccines & Therapeutics
- G-CSF & GM-CSF
- PTH-R Agonists
- Cardiometabolic Peptides
- Immune Checkpoint Modulators
Examples of Predefined Technologies of the Scroll Down Menu:
- Transgenic XenoMouse Antibodies
- T-Cell Redirecting Bispecific Antibodies
- ADC - Pyrrolobenzodiazepine (PBD)
- Fc-Fusion Proteins
- Oligo- and Polyclonal Antibodies
For more information about this newsletter visit https://www.researchandmarkets.com/research/9l5dcs/randd_drug
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Discovery


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Instagram Outage Disrupts Thousands of U.S. Users
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 



